Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

Amneal Pharmaceuticals (NASDAQ:AMRX) outlined plans to acquire Kashiv BioSciences and reported preliminary first-quarter results during an investor call, with executives describing the deal as a strategic move to build a vertically integrated biosimilars platform and extend the company’s growth prof

Amneal to buy a biosimilar company; Samsung Bio workers protest

Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is set to buy ...